Zentalis Pharmaceuticals, Inc. Income Tax Expense (Benefit) in USD from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Zentalis Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2019 to Q3 2025.
  • Zentalis Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $0.000.
  • Zentalis Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was -$205K, a 183% decline year-over-year.
  • Zentalis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2024 was $177K.
  • Zentalis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was -$601K, a 28.1% decline from 2022.
  • Zentalis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was -$469K, a 57.9% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

Zentalis Pharmaceuticals, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$205K $0 +$27K Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$232K $0 -$266K -100% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-06
Q1 2025 $34K $0 -$143K -100% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $177K -$205K -$70K -51.9% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-26
Q3 2024 $247K -$27K -$58K -187% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 $305K $266K +$871K Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-06
Q1 2024 -$566K $143K +$35K +32.4% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 -$601K -$135K +$225K +62.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-26
Q3 2023 -$826K $31K +$190K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$1.02M -$605K -$622K -3659% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$394K $108K +$75K +227% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$469K -$360K -$519K -326% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-26
Q3 2022 $50K -$159K +$538K +77.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$488K $17K -$28K -62.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$460K $33K -$163K -83.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$297K $159K -$267K -62.7% Oct 1, 2021 Dec 31, 2021 10-K 2022-02-24
Q3 2021 -$30K -$697K -$715K -3972% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $685K $45K +$45K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $640K $196K +$196K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $444K $426K +$426K Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 $18K $18K +$17K +1700% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-24
Q2 2020 $1K $0 -$11K -100% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-24
Q1 2020 $12K $0 -$3K -100% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-24
Q4 2019 $15K $0 Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $1K Jul 1, 2019 Sep 30, 2019 10-K 2021-03-25
Q2 2019 $11K Apr 1, 2019 Jun 30, 2019 10-K 2021-03-25
Q1 2019 $3K Jan 1, 2019 Mar 31, 2019 10-K 2021-03-25

Zentalis Pharmaceuticals, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $177K +$778K Jan 1, 2024 Dec 31, 2024 10-K 2025-03-26
2023 -$601K -$132K -28.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-26
2022 -$469K -$172K -57.9% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-26
2021 -$297K -$741K -167% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $444K +$429K +2860% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 $15K Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.